(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 November 2018 (08.11.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/204427 A1

(51) International Patent Classification:
A61K 35/17 (2015.01) *A61P 35/00* (2006.01)
A61K 31/454 (2006.01)

(21) International Application Number:
PCT/US2018/030545

(22) International Filing Date:
01 May 2018 (01.05.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/492,947	01 May 2017 (01.05.2017)	US
62/538,670	29 July 2017 (29.07.2017)	US
62/549,390	23 August 2017 (23.08.2017)	US
62/580,433	01 November 2017 (01.11.2017)	US
62/596,753	08 December 2017 (08.12.2017)	US

(71) Applicant: **JUNO THERAPEUTICS, INC.** [US/US]; 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US).


(72) Inventors: **PORTS, Michael**; C/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US). **WORKS, Melissa**; C/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US).

(74) Agent: **POTTER, Karen** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

(54) Title: COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND

FIG. 1A



(57) Abstract: The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.

WO 2018/204427 A1

[Continued on next page]

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*